For patients with advanced neurotrophic keratitis, a severe ulcerative form of corneal blindness, standard care starts with lubrication and antibiotics. It progresses to amniotic transplants or tarsorrhaphy. Many end with donor transplants risking rejection [PharmaSource].
Pandorum Technologies, Bengaluru-based and founded in 2011, bets Kuragenx offers scarless alternative. It raised $11 million Series B led by Protons Corporate for trials [PharmExec].
A Clinical Push for a Bioengineered Cornea
Pandorum focuses on getting Kuragenx to patients. It pursues clinical manufacturing and IND studies, aiming first dose 2025 [Eyewire+].
CDMO with AGC Biologics eyes U.S., Europe. Nucelion collaboration aids India [PharmiWeb]. Dual tracks navigate regulations.
The Founders and Their Long-Term Platform
Co-founders Arun Chandru and Tuhin Bhowmick came from IISc. Chandru earned Forbes Asia 30 Under 30 [Forbes].
Platform uses 3D printing, self-assembly for liver, neuronal too [BioSpectrum India]. Kuragenx validates toolkit.
Funding shows belief.
2018 Series A | 3.6 | M USD
2024 Series B | 11 | M USD
Total Disclosed | 24.1 | M USD
Backers: Binny Bansal, Sachin Bansal, Sunil Munjal, TK Kurien, IAN, 500 Startups [Perplexity Sonar Pro]. Grants from Department of Biotechnology.
Navigating a High-Risk, High-Reward Field
Regenerative medicine promises much, risks steep. Pandorum weighs execution.
- Clinical validation. Pre-clinical to human leap greatest risk. Kuragenx needs safety, superior efficacy.
- A crowded cornea field. Faces CorneaGen, Aurion Biotech on tissue, cells. Differentiation key.
- The commercial pathway. Approval needs reimbursement, surgeon training, procurement.
L.V. Prasad partnership assets for validation, adoption [YourStory, May 2019].
For patients, liquid beats fixes, surgery. Next year decisive for clinical shift. Success signals India deep tech.
Sources
- [PharmaSource, Unknown] Kuragenx for neurotrophic keratitis | https://pharmasource.com
- [PharmExec, Unknown] Pharma Funding Roundup | https://www.pharmexec.com/view/pharma-funding-roundup-quantx-biosciences-pandorum-technologies-complete-series-b-financing-rounds
- [Eyewire+, Unknown] Pandorum clinical timeline | https://eyewire.news
- [PharmiWeb, Unknown] Pandorum partnerships | https://www.pharmiweb.com
- [Forbes, Unknown] Forbes Asia 30 Under 30 | https://www.forbes.com/profile/chandru-raheja/?list=billionaires
- [BioSpectrum India, Unknown] Pandorum platform technology | https://www.biospectrumindia.com/news/86/24392/pandorum-technologies-raises-11-m-to-advance-regenerative-therapy-for-corneal-blindness-to-clinical-phase.html
- [Perplexity Sonar Pro, Unknown] Company overview and funding | https://www.perplexity.ai
- [YourStory, May 2019] Collaboration with L.V. Prasad Eye Institute | https://yourstory.com/2019/05/biotech-startup-pandorum-technologies-human-cornea-tissue